Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia (CLARITY)

This study has been terminated.
(pre-planned interim analysis of the Phase II/III CLARITY trial of BL-1020 indicate that the trial would not meet the pre-specified primary efficacy endpoint.)
Sponsor:
Information provided by (Responsible Party):
BioLineRx, Ltd.
ClinicalTrials.gov Identifier:
NCT01363349
First received: May 30, 2011
Last updated: September 17, 2014
Last verified: September 2014

May 30, 2011
September 17, 2014
May 2011
March 2013   (final data collection date for primary outcome measure)
Cognition [ Time Frame: Baseline and 6 weeks ] [ Designated as safety issue: No ]
To evaluate the cognitive benefits of treatment with CYP-1020 (formerly known as BL-1020) compared to risperidone after 6 weeks of treatment in patients experiencing acute exacerbation of schizophrenia. Assessed by calculating difference between CYP-1020 and Risperidone on mean change from baseline to Week 6 endpoint on MATRICS Consensus Cognition Battery (MCCB) normative composite score. MCCB is a neuropsychological test battery that comprises 10 measures of 7 different cognitive areas including speed of processing, verbal learning, memory-verbal and non verbal reasoning and problem solving, visual learning, social cognition, attention/vigilance.The study was terminated after the interim analysis. MCBB total score ranges from -50 to 150. Change from Baseline by Visit (LOCF)Higher score means better cognitive functioning.
  • Cognition [ Designated as safety issue: No ]
    To evaluate the cognitive benefits of treatment with CYP-1020 (formerly known as BL-1020) compared to risperidone and placebo after 6 weeks of treatment in patients experiencing acute exacerbations of schizophrenia
  • Schizophrenia treatment [ Designated as safety issue: No ]
    To evaluate the antipsychotic efficacy of CYP-1020 compared to placebo after 6 weeks of treatment in patients experiencing acute exacerbations of schizophrenia
Complete list of historical versions of study NCT01363349 on ClinicalTrials.gov Archive Site
  • Long Term Cognition [ Time Frame: 12 and 24 weeks of treatment ] [ Designated as safety issue: No ]
    Evaluation of the cognitive benefits of treatment with BL-1020 compared to risperidone after 12 and 24 weeks of treatment
  • Long Term Schizophrenia Treatment [ Time Frame: Baseline and 6, 12 and 24 weeks of treatment ] [ Designated as safety issue: No ]
    Evaluation of the antipsychotic efficacy of BL-1020 compared to risperidone after 6, 12 and 24 weeks of treatment
  • Long term cognition [ Designated as safety issue: No ]
    Evaluation of the cognitive benefits of treatment with CYP-1020 compared to risperidone after 12 and 24 weeks of treatment
  • Long term schizophrenia treatment [ Designated as safety issue: No ]
    Evaluation of the antipsychotic efficacy of CYP-1020 compared to risperidone after 6, 12 and 24 weeks of treatment
Not Provided
Not Provided
 
Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia
A Randomized, Double-Blind, Active-Controlled,Phase 2/3 Study to Determine the Short-Term (6-Week) and Long-Term (6 Month) Cognitive and Anti-Psychotic Efficacy, Safety and Tolerability of CYP-1020 Compared to Risperidone in Patients With Schizophrenia

This is a randomized, double-blind, active-controlled, 6 month study designed to evaluate the cognitive effects of treatment with CYP-1020 compared to risperidone. The primary efficacy endpoint will occur after 6 weeks of treatment; additional (secondary) efficacy endpoints will occur after 12 and 24 weeks of treatment.

Up to 450 patients will be randomized to CYP-1020 or risperidone in a 1:1 ratio. The study will utilize a flexible dose escalation scheme designed to allow patients to titrate to their maximally tolerated dose; doses of CYP-1020 may range from a minimum of 15 mg to a maximum of 35 mg, whereas doses of risperidone will range from a minimum of 1 mg to 3 mg BID (2-6 mg daily). To ensure effective blinding across all treatment groups, all patients will be treated twice daily with study drug and/or placebo, as indicated (i.e., double-dummy design).

Not Provided
Interventional
Phase 2
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
  • Schizophrenia
  • Cognitive Effect on Schizophrenic Patients
  • Drug: CYP-1020
    CYP-1020 (formerly known as BL-1020) is an orally available new chemical entity.
    Other Name: BL-1020
  • Drug: Risperidone
  • Experimental: CYP-1020
    Dose titration 15-35mg/day for 6 months
    Intervention: Drug: CYP-1020
  • Active Comparator: Risperidone
    Dose titration 2-6mg/day for 6 months
    Intervention: Drug: Risperidone
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
269
April 2013
March 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male or non-pregnant or lactating female, 18-50 years of age inclusive
  2. Patients must have exhibited symptoms meeting the criteria of schizophrenia for at least one year, but not more than 20 years, prior to Screening
  3. Recent onset (not more than 30 days) of worsening of psychiatric symptoms at Screening.
  4. Currently experiencing an acute exacerbation of schizophrenia, as defined by the following results at Screening and Baseline:

    • ≥70 total score on the PANSS
    • ≥4 (moderate) on two of the following four PANSS items: (1) delusions, (2) hallucinatory behaviors, (3) conceptual disorganization or (4) suspiciousness/persecution, where at least one of the two items must be either delusions or hallucinatory behaviors
  5. CGI-S score between 4 and 6 (moderately ill to severely ill) at the Screening and Baseline visits.
  6. Has exhibited a sufficient clinical response to at least one previous course of an anti-psychotic agent prescribed at a generally recognized therapeutic dose.
  7. Must have completed at least 5 years of formal education or its equivalent

Exclusion Criteria:

  1. Breastfeeding or pregnant
  2. Symptoms of schizophrenia for more than 20 years at the time of screening.
  3. Psychotic symptoms that have failed to improve (based on Investigator's opinion or documented medical history) following sufficient treatment with therapeutic doses of two or more anti-psychotics agents over the preceding 2 years
  4. Prior history of neuroleptic malignant syndrome
  5. Prior history or current evidence of moderate or severe tardive dyskinesia (mild is acceptable).
  6. Abnormal ECG evaluation
  7. History of confirmed epilepsy or prior seizure disorder (history of a single febrile seizure is not exclusionary)
  8. In the opinion of the investigator, unstable medical disease (e.g., malignancy, poorly controlled diabetes or hypertension, ischemic cardiac disease, dilated cardiomyopathy or valvular heart disease, pulmonary disease, liver disease, kidney disease)
  9. Acute infectious disease (e.g., malaria, dengue fever, hepatitis A), or chronic infectious disease (e.g., history of AIDS or HIV positivity, tuberculosis)
  10. Likely allergy, sensitivity or intolerance to BL-1020, perphenazine, risperidone, paliperidone, or any of the drug product excipients
  11. Any suicide attempt within the preceding 2 years
  12. Any Substance Dependence disorder
  13. High likelihood of substance abuse
  14. Diagnosis with one of the following DSM-IV-TR Axis I diagnoses: schizophreniform disorder, schizoaffective disorder, bipolar disorder, substance dependency, mood disorder with psychotic features; psychotic disorder NOS
  15. Requiring chronic treatment with benzodiazepines
  16. Requiring chronic treatment with mood stabilizers
  17. Previously treated with clozapine within 6 months prior to screening
  18. Any abnormal clinical laboratory test result that is judged by the Investigator to be clinically significant
  19. History of, or serologic evidence of, acute or chronic active hepatitis B or C
Both
18 Years to 50 Years
No
Contact information is only displayed when the study is recruiting subjects
India,   Moldova, Republic of,   Romania
 
NCT01363349
1020-CLIN-201
No
BioLineRx, Ltd.
BioLineRx, Ltd.
Not Provided
Study Chair: Arnon Aharon, MD BioLineRx, Ltd.
BioLineRx, Ltd.
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP